Medline has put forward terms for an absolutely massive IPO, which could see the medical device manufacturing and ...

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a ...

After announcing plans to split up the company near the top of this year, Teleflex said it has found new homes for its ...

The FDA has cleared the first artificial intelligence (AI) drug development tool to help evaluate fatty liver disease in ...

OSE Immunotherapeutics is prioritizing its lung cancer med Tedopi and shifting the strategy for its ulcerative colitis (UC) ...

Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost 90% of patients in a phase ...

Novartis is divulging details from ianalumab’s summertime | Novartis is divulging details from ianalumab’s phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could del ...

Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by ...